Related Experiment Videos
[Heart failure. New concepts, new medications]
1Servicio de Cardiología en el Centro Médico Paitilla, Facultad de Medicina de la Universidad de Panamá.
Insights
A combination of ACE inhibitors, diuretics, and digitalis improved survival and function in advanced systolic heart failure patients. Increased use of antiarrhythmics like Amiodarone and anticoagulants like Warfarin is suggested for better outcomes.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Advanced cardiac insufficiency with systolic myocardial dysfunction presents significant challenges.
- Atherosclerotic heart disease confers a slightly better prognosis than dilated idiopathic congestive cardiomyopathy in heart failure patients.
Purpose:
- To evaluate the efficacy of combined ACE inhibitors, diuretics, and digitalis in managing advanced systolic heart failure.
- To assess the potential benefits of increasing Amiodarone and Warfarin use for arrhythmias and embolism prevention.
Summary:
- A 68% survival rate and improved functional capacity were achieved using ACE inhibitors, diuretics, and digitalis.
- Atherosclerotic heart disease patients showed a better prognosis compared to those with dilated cardiomyopathy.
- Underutilization of Amiodarone (26%) and Warfarin (26%) suggests a need for increased application to mitigate risks of arrhythmias, sudden death, and embolism.
Impact:
- The findings support the current therapeutic regimen for systolic heart failure.
- Highlights the need for broader application of specific antiarrhythmic and anticoagulant therapies to improve patient outcomes and reduce mortality.
Abstract:
It is possible, in our midst, to obtain a survival rate of 68% and a marked improvement in the functional capacity of patients with advanced cardiac insufficiency due to systolic myocardial dysfunction through the combined use of ACE inhibitors, diuretics and digitalis as the main therapeutic agents. Patients with cardiac failure due to atherosclerotic heart disease have a slight better prognosis than those whose failure is secondary to dilated idiopathic congestive cardiomyopathy. The incidence of arrhythmias, sudden death and peripheral embolism suggest that the use of Amiodarone as antiarrhythmic agent and of Warfarin as anticoagulant should be increased. Each of these agents was used in only 26% of our patients.